journal article·2022-03Open access

Potentialities of nanomaterials for the management and treatment of metabolic syndrome: A new insight

Charles Oluwaseun Adetunji, Olugbenga Samuel Michael, Shweta Rathee, Kshitij RB Singh, Olulope Olufemi Ajayi, Juliana Bunmi Adetunji, Ankur Ojha, Jay Singh, Ravindra Pratap Singh

Abstract

Metabolic syndrome is a collection of abnormalities including insulin resistance, hypertension, dyslipidemia, type 2 diabetes, obesity, inflammation, non-alcoholic fatty liver disease, etc. The metabolic syndrome results in a dramatic five-fold elevation in the risk of developing type-2 diabetes and a two-fold heightened risk of developing cardiovascular diseases. It is fast becoming a major global health challenge, cause of mortality and morbidity. Regardless of advances in understanding the mechanisms involved in the pathogenesis of metabolic syndrome, available therapies are still not effective. Nanotechnology is marked as an upcoming tool with a wide range of applications in biomedicine, especially for the management of metabolic syndrome and its associated disorders such as diabetes, obesity, etc. because the nanotechnology utilizes nanoscaled drugs and therapeutics that can reach specific target sites, which helps in improving drug delivery systems, early disease detection and diagnosis using nano-imaging techniques. Therefore, nanotechnology increases bioavailability, permeability, compatibility, the effectiveness of treatment and reduced adverse effects. In this review, we will describe the role of nanomaterial-based therapeutics in managing metabolic disorders such as non-alcoholic fatty liver disease, obesity, insulin resistance, glucose intolerance which all increase the risk of developing cardiovascular diseases and diabetes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Liver Disease Diagnosis and Treatment · Metabolomics and Mass Spectrometry Studies · Natural Antidiabetic Agents Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Metabolic syndrome: definitions and controversies
2. Harmonizing the metabolic syndrome10.1161/CIRCULATIONAHA.109.192644 ↗
3. The global epidemic of the metabolic syndrome,10.1007/s11906-018-0812-z ↗
4. Association of the metabolic syndrome with both vigorous and moderate physical activity10.1093/ije/dyg179 ↗
5. Recent advances in nanotechnology for the treatment of metabolic syndrome., Diabetes Metab
6. Nanoformulations of natural products for management of metabolic syndrome10.2147/IJN.S213831 ↗
7. Nanotechnology-mediated drug delivery for the treatment of obesity and its related comorbidities10.1002/adhm.201801184 ↗
8. Exosomes and miRNA-loaded biomimetic nanovehicles, a focus on their potentials preventing type-2 diabetes linked to metabolic syndrome, front
9. A novel dual-targeted rosiglitazone-loaded nanoparticle for the prevention of diet-induced obesity via the browning of white adipose tissue,10.1016/j.jconrel.2020.10.002 ↗
10. Low-dose curcumin nanoparticles normalise blood pressure in male wistar rats with diet-induced metabolic syndrome10.3390/nu11071542 ↗
11. Effects of daily consumption of an aqueous dispersion of free-phytosterols nanoparticles on individuals with metabolic syndrome: a randomised, double-blind, placebo-controlled clinical trial,10.3390/nu12082392 ↗
12. Nanophytomedicines for the prevention of metabolic syndrome: a pharmacological and biopharmaceutical review, front. Bioeng
13. Increased oxidative stress in obesity and its impact on metabolic syndrome10.1172/JCI21625 ↗
14. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds10.1177/1753944717711379 ↗
15. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism.,10.5551/jat.7922 ↗
16. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects10.2337/diabetes.52.12.2882 ↗
17. Adverse endothelial function and the insulin resistance syndrome10.1046/j.1365-2796.2000.00671.x ↗
18. Plasma leptin and the risk of cardiovascular disease in the west of scotland coronary prevention study (WOSCOPS)10.1161/hc5001.101061 ↗
19. Adiponectin and development of type 2 diabetes in the Pima Indian population10.1016/S0140-6736(02)09335-2 ↗
20. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system, Am10.1152/ajpcell.00287.2006 ↗
21. Triad of metabolic syndrome, chronic kidney disease, and coronary heart disease with a focus on microalbuminuria10.1016/j.jacc.2011.02.027 ↗
22. LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells10.1016/j.bbrc.2013.06.035 ↗
23. Tumor necrosis factor alpha inhibits signaling from the insulin receptor., Proc. Natl. Acad. Sci. U
24. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity10.1016/S0026-0495(99)90277-9 ↗
25. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss∗
26. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity,10.1097/01.ASN.0000141966.69934.21 ↗
27. Anthocyanins in the management of metabolic syndrome: a pharmacological and biopharmaceutical review, front
28. Nanoformulations of curcumin: an emerging paradigm for improved remedial application10.18632/oncotarget.19164 ↗
29. Effect of nanoencapsulation using PLGA on antioxidant and antimicrobial activities of guabiroba fruit phenolic extract10.1016/j.foodchem.2017.07.144 ↗
30. SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: an insight into its mechanism for neuroprotection, Nanomedicine Nanotechnology, Biol
31. Anti-obesity efficacy of nanoemulsion oleoresin capsicum in obese rats fed a high-fat diet
32. O-Hexadecyl-Dextran entrapped berberine nanoparticles abrogate high glucose stress induced apoptosis in primary rat hepatocytes10.1371/journal.pone.0089124 ↗
33. Nanostructured lipid carriers loaded with baicalin: an efficient carrier for enhanced antidiabetic effects10.4103/0973-1296.186347 ↗
34. Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model, Drug Deliv
35. Preparation of a nano emodin transfersome and study on its anti-obesity mechanism in adipose tissue of diet-induced obese rats, J. Transl. Med
36. Studies on gymnemic acids nanoparticulate formulations against diabetes mellitus10.4018/ijbce.2012070101 ↗
37. Nanodiamond enhances immune responses in mice against recombinant HA/H7N9 protein10.1186/s12951-017-0305-2 ↗
38. Nanoliposomal resveratrol as a novel approach to treatment of diabetes mellitus10.1166/jnn.2018.15247 ↗
39. Engineered silybin nanoparticles educe efficient control in experimental diabetes10.1371/journal.pone.0101818 ↗
40. Solid lipid nanoparticles of myricitrin have antioxidant and antidiabetic effects on streptozotocin-nicotinamide-induced diabetic model and myotube cell of male mouse10.1155/2018/7496936 ↗
41. Development of stevioside Pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine10.1016/j.colsurfb.2012.07.005 ↗
42. Comparative prophylactic effects of α-eleostearic acid rich nano and conventional emulsions in induced diabetic rats10.1007/s13197-014-1257-2 ↗
43. Dietary phytochemicals and their potential effects on obesity: a review,10.1016/j.phrs.2011.07.004 ↗
44. In vitro/vivo drug release and anti-diabetic cardiomyopathy properties of curcumin/PBLG-PEG-PBLG nanoparticles, Int
45. Nanoparticle-encapsulated curcumin inhibits diabetic neuropathic pain involving the P2Y12 receptor in the dorsal root ganglia, front
46. Ganguly chaiti, cytotoxic potential of Indian spices (extracts) against esophageal squamous carcinoma cells
47. Red pepper ( capsicum baccatum ) extracts present anti-inflammatory effects in vivo and inhibit the production of TNF-α and NO10.1089/jmf.2015.0101 ↗
48. Induction of apoptosis by berberine in hepatocellular carcinoma HepG2 cells via downregulation of NF-κB10.3727/096504016X14742891049073 ↗
49. Rhizoma as potential anticancer agents: recent updates and future perspectives10.1016/j.jep.2015.10.028 ↗
50. Hormetic effect of berberine attenuates the anticancer activity of chemotherapeutic agents10.1371/journal.pone.0139298 ↗
51. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients, evidence-based complement. Altern
52. Berberine encapsulated PLGA-PEG nanoparticles modulate PCSK-9 in HepG2 cells10.2174/1871529X18666180201130340 ↗
53. Antioxidant properties, radical scavenging activity and biomolecule protection capacity of flavonoid naringenin and its glycoside naringin: a comparative study10.1002/jsfa.3959 ↗
54. Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation, Diabetes, Obes
55. Naringenin protects against cadmium-induced oxidative renal dysfunction in rats10.1016/j.tox.2008.11.012 ↗
56. Alginate coated chitosan core-shell nanoparticles for efficient oral delivery of naringenin in diabetic animals—an in vitro and in vivo approach10.1016/j.carbpol.2017.04.066 ↗
57. Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo10.3892/or.2017.5766 ↗
58. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese zucker rats10.1038/oby.2008.315 ↗
59. Preparation, characterization and in vivo evaluation of pH sensitive, safe quercetin-succinylated chitosan-alginate core-shell-corona nanoparticle for diabetes treatment10.1016/j.carbpol.2017.10.098 ↗
60. Emodin, a protein tyrosine kinase inhibitor from polygonum cuspidatum10.1021/np50083a026 ↗
61. Emodin: a review of its pharmacology, toxicity and pharmacokinetics,10.1002/ptr.5631 ↗
62. Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia10.1007/s11302-017-9583-2 ↗
63. Gymnema sylvestre (gurmar): a review,
64. Baicalin improves antioxidant status of streptozotocin-induced diabetic wistar rats10.1021/jf8028539 ↗
65. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders10.1016/j.ejmech.2017.03.004 ↗
66. Determination of scutellarin in mouse plasma and different tissues by high-performance liquid chromatography10.1016/j.jchromb.2006.02.041 ↗
67. Combined therapy of diabetic peripheral neuropathy with breviscapine and mecobalamin: a systematic review and a meta-analysis of Chinese studies,
68. What we talk about when we talk about fat10.1016/j.cell.2013.12.012 ↗
69. The portal theory supported by venous drainage–selective fat transplantation,10.2337/db10-0697 ↗
70. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics10.3920/BM2012.0065 ↗
71. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity10.1111/obr.12370 ↗
72. Role of microbiota-derived lipopolysaccharide in adipose tissue inflammation, adipocyte size and pyroptosis during obesity10.1017/S0954422417000269 ↗
73. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion10.1089/met.2014.0082 ↗
74. Cellular and molecular effects of resveratrol in health and disease10.1002/jcb.23431 ↗
75. Resveratrol nano-capsule as an effi cient tool for blood pressure regulation: a study on metabolic syndrome induced mice, Biosci10.21786/bbrc/10.4/4 ↗
76. Quantitation of silibinin, a putative cancer chemopreventive agent derived from milk thistle ( Silybum marianum ), in human plasma by high-performance liquid chromatography and identification of possible metabolites10.1021/jf063156c ↗
77. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: a review,10.1002/ptr.6153 ↗
78. Myricitrin, a nitric oxide and protein kinase C inhibitor, exerts antipsychotic-like effects in animal models10.1016/j.pnpbp.2011.06.002 ↗
79. Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE−/− mice10.1016/j.taap.2013.04.015 ↗
80. Goyal
81. Essential Oils in Food Preservation · 2016
82. Experimental and computational study of naphthalimide derivatives: synthesis, optical, nonlinear optical and antiviral properties10.1016/j.ijleo.2021.167748 ↗
83. Substituted phenothiazines: synthesis and in silico evaluation of D4 dopamine receptor inhibition10.1007/s42452-020-3067-7 ↗
84. A novel ternary NiFe2O4/CuO/FeO-chitosan nanocomposite as a cholesterol biosensor,10.1016/j.procbio.2012.08.012 ↗
85. Biomedical applications of carboxymethyl chitosans10.1016/j.carbpol.2012.07.076 ↗
86. Singh · 2021 · 1
87. Recent applications of magnesium oxide (MgO) nanoparticles in various domains10.5185/amlett.2020.081543 ↗
88. Singh · 2012 · 215
89. Singh · 2014 · 141
90. Singh · Introduction to bionanomaterials: an overview, in: Bionanomaterials, IOP Publishing · 2021
91. Singh · 2021
92. Adetunji · 2021 · 129
93. Cerium oxide nanoparticles: properties, biosynthesis and biomedical application10.1039/D0RA04736H ↗
94. Potentialities of selenium nanoparticles in biomedical science10.1039/D0NJ05884J ↗
95. Potential applications of peptide nucleic acid in biomedical domain, Eng
96. Nanoparticle delivery systems in the treatment of diabetes complications10.3390/molecules24234209 ↗
97. Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment10.1016/j.jconrel.2017.09.003 ↗
98. Nanotechnology based approaches for anti-diabetic drugs delivery10.1016/j.diabres.2017.11.018 ↗
99. Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities10.1111/jphp.12607 ↗
100. Tolerogenic nanoparticles to treat islet autoimmunity10.1007/s11892-017-0914-z ↗